Experimental ALS Therapy Stabilized Patient Function
Researchers in Jacksonville used a gene-targeted approach to reduce nerve damage in a rare form of ALS.
Updated on Oct. 1, 2026 in Stroke
Live Poll
Should medical research prioritize the development of personalized genetic therapies for rare diseases?
Mayo Clinic researchers published findings from a single-patient study where an experimental antisense oligonucleotide therapy helped stabilize a person with a rare genetic form of ALS. The intervention, which reduced a key biomarker for nerve damage by 50%, marks a milestone in developing precision medicine for rare neurodegenerative conditions.
Why it matters
This case highlights how scientists are now targeting the specific genetic drivers of rare ALS subtypes rather than treating the disease as a single condition. The approach offers a potential template for managing other neurodegenerative disorders by addressing the underlying protein production at the source.
In a single-patient case study, researchers evaluated an experimental antisense oligonucleotide therapy after screening over 320 candidates. The patient showed a 50% decline in neurofilament light levels, a marker of nerve-cell injury, while clinical function remained stable.
The players
Mayo Clinic
A nonprofit medical center specializing in complex care and clinical research across diverse medical fields.
n-Lorem Foundation
A non-profit organization dedicated to developing experimental antisense oligonucleotide treatments for ultrarare genetic diseases.
Rosa Rademakers
A geneticist and 2026 Breakthrough Prize winner known for her work on ALS-related gene mutations.
The details
The experimental therapy uses antisense oligonucleotides, which are molecules designed to bind to RNA and stop the production of harmful proteins linked to the CHCHD10 gene mutation. By injecting these molecules directly into the patient's spinal cord fluid, the treatment successfully targeted the genetic origin of this rare ALS form. This reduction in abnormal protein expression resulted in measurable improvements or stabilization in the patient's breathing, cognition, and physical movement.
Timeline
2011: Rosa Rademakers helped discover the C9orf72 gene mutation.
2026: Rosa Rademakers received the Breakthrough Prize.
October 1, 2026: Mayo Clinic researchers published the study findings.
Health Landscape
This development marks a shift toward N-of-1 trial models where therapies are customized to a single patient's unique genetic mutation. It builds on the broader landscape of ALS research, which seeks to isolate genetic drivers like those identified by Rosa Rademakers to create more precise interventions.
While this treatment is not standard care, it emphasizes the importance of genetic testing for those with a family history of neurodegenerative disease. If you are managing ALS, it is worth discussing the latest clinical research and genetic testing options with your neurologist.
The takeaway
This case demonstrates that targeted genetic therapies can effectively reduce markers of nerve-cell damage in patients with specific ALS mutations. Residents interested in clinical research progress should continue to monitor updates on gene-silencing technologies for neurodegenerative diseases.
Further reading
For more information on current neurodegenerative research, visit the Stroke section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should medical research prioritize the development of personalized genetic therapies for rare diseases?
